Maternal Use of Drugs for Nausea and Vomiting in Pregnancy and Infant Congenital Malformations
Use of drugs for nausea and vomiting in pregnancy (NVP) is associated with a tendency to a slightly reduced risk for congenital malformations. This is probably not an effect of the drugs but a sign that moderate NVP may be a result of a well-functioning placenta. The only exception concerns ondansetron which has been linked to an increased risk for cardiovascular defects, notably septum defects. This association is not definitely proved but it may be a good idea to avoid this drug during the first trimester. This, of course, does not prevent its use later in pregnancy, when the serious condition of hyperemesis gravidarum usually occurs.
- Andersen JT, Jimenez-Solem E, Andersen NL, Poulsen HE. Ondansetron use in early pregnancy and the risk of congenital malformations—a registry based nationwide cohort study. Montreal: International Society of Pharmaco-Epidemiology; 2013. Abstract 25. Pregnancy session 1.Google Scholar
- Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977.Google Scholar